Symbols / CAI Stock $17.77 +14.76% Caris Life Sciences, Inc.
CAI (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteCaris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.
Ratings
Current target
$17.83
Low
$21.00
High
$36.00
Mean
$27.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-05-08 | main | Citigroup | Buy → Buy | $28 |
| 2026-05-08 | main | JP Morgan | Overweight → Overweight | $30 |
| 2026-05-08 | main | BTIG | Buy → Buy | $32 |
| 2026-04-13 | init | Jefferies | — → Buy | $28 |
| 2026-04-10 | init | Piper Sandler | — → Neutral | $21 |
| 2026-04-06 | main | Evercore ISI Group | Outperform → Outperform | $30 |
| 2026-03-13 | main | Canaccord Genuity | Hold → Hold | $22 |
| 2026-02-27 | main | Evercore ISI Group | Outperform → Outperform | $34 |
| 2026-02-27 | main | Baird | Outperform → Outperform | $28 |
| 2026-02-27 | main | BTIG | Buy → Buy | $38 |
| 2026-02-17 | init | Baird | — → Outperform | $26 |
| 2025-12-22 | main | Canaccord Genuity | Hold → Hold | $30 |
| 2025-12-02 | init | Canaccord Genuity | — → Hold | $28 |
| 2025-08-13 | main | Guggenheim | Buy → Buy | $36 |
| 2025-08-13 | main | Evercore ISI Group | Outperform → Outperform | $40 |
| 2025-08-13 | main | Citigroup | Buy → Buy | $42 |
| 2025-07-15 | init | Evercore ISI Group | — → Outperform | $33 |
| 2025-07-14 | init | TD Cowen | — → Buy | $32 |
| 2025-07-14 | init | Guggenheim | — → Buy | $32 |
| 2025-07-14 | init | Wolfe Research | — → Outperform | $32 |
News
RSS: Latest CAI news- Trade Caris Life Sciences Inc - CAI CFD - Capital.com hu, 04 Jun 2026 05
- Caris Life (CAI) director granted 1,600 shares for 2026 board fees - Stock Titan ue, 02 Jun 2026 21
- You’ve Likely Never Heard of Caris Life Sciences Stock. Billionaire Stanley Druckenmiller Has – and He Likes What He Sees. - Yahoo Finance Wed, 20 May 2026 07
- Caris Life Sciences (CAI) Earnings Date and Reports 2026 $CAI - MarketBeat Wed, 03 Jun 2026 02
- Is It Time To Reconsider Caris Life Sciences (CAI) After 26.5% Year To Date Decline? - simplywall.st Fri, 08 May 2026 07
- Caris Life Sciences Stock Is Down 29% in 2026. . Here’s Why ChromoSeq and Detect Could Change the Trajectory - TIKR.com hu, 07 May 2026 07
- Labor Is The Major Overhang On Boeing's Stock, Says TD Cowen's Cai Von Rumohr Caspian Sea (VptdSlGsIp) - Mshale Sun, 31 May 2026 22
- Caris Life Sciences Reports First Quarter 2026 Financial Results - PR Newswire hu, 07 May 2026 07
- Caris Life Sciences, Inc. ($CAI) CEO 2025 Pay Revealed | CAI Stock News - Quiver Quantitative hu, 23 Apr 2026 07
- CAI.VI Stock Price, Quote & Chart | CA IMMOBILIEN ANLAGEN AG (VIE:CAI) - ChartMill Fri, 29 May 2026 07
- Director takes Caris Life Sciences (CAI) 2026 board fees in stock - Stock Titan ue, 02 Jun 2026 21
- Assessing Caris Life Sciences (CAI) Valuation As Shares Trade Below Narrative Fair Value - Yahoo Finance Fri, 08 May 2026 07
- JPMorgan Chase & Co. Issues Pessimistic Forecast for Caris Life Sciences (NASDAQ:CAI) Stock Price - MarketBeat Fri, 08 May 2026 07
- Caris Life Sciences, Inc.'s (NASDAQ:CAI) Shares May Have Run Too Fast Too Soon - simplywall.st hu, 05 Feb 2026 08
- Alan Waxman and TSSP Sub‑Fund HoldCo report stakes in CARIS Life Sciences (NASDAQ: CAI) - Stock Titan ue, 12 May 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
812.03
+96.97%
|
412.26
+34.67%
|
306.13
+18.43%
|
258.49
|
| Operating Revenue |
|
812.03
+96.97%
|
412.26
+34.67%
|
306.13
+18.43%
|
258.49
|
| Cost Of Revenue |
|
272.87
+16.87%
|
233.48
+7.68%
|
216.82
+21.49%
|
178.46
|
| Reconciled Cost Of Revenue |
|
272.87
+16.87%
|
233.48
+7.68%
|
216.82
+21.49%
|
178.46
|
| Gross Profit |
|
539.17
+201.58%
|
178.78
+100.18%
|
89.31
+11.61%
|
80.02
|
| Operating Expense |
|
494.06
+13.34%
|
435.90
+6.61%
|
408.86
+3.31%
|
395.78
|
| Research And Development |
|
101.58
-10.83%
|
113.92
-2.54%
|
116.88
+15.42%
|
101.27
|
| Selling General And Administration |
|
392.47
+21.89%
|
321.99
+10.28%
|
291.98
-0.86%
|
294.51
|
| Selling And Marketing Expense |
|
167.51
+9.77%
|
152.60
+6.77%
|
142.93
+3.30%
|
138.36
|
| General And Administrative Expense |
|
224.97
+32.81%
|
169.39
+13.64%
|
149.05
-4.55%
|
156.15
|
| Salaries And Wages |
|
—
|
12.75
+22.79%
|
10.38
|
—
|
| Other Gand A |
|
224.97
+32.81%
|
169.39
+13.64%
|
149.05
-4.55%
|
156.15
|
| Total Expenses |
|
766.92
+14.57%
|
669.38
+6.98%
|
625.68
+8.96%
|
574.24
|
| Operating Income |
|
45.11
+117.55%
|
-257.12
+19.54%
|
-319.55
-1.20%
|
-315.76
|
| Total Operating Income As Reported |
|
45.11
+117.55%
|
-257.12
+19.54%
|
-319.55
-1.20%
|
-315.76
|
| EBITDA |
|
11.38
+106.22%
|
-182.95
+29.85%
|
-260.80
-6.06%
|
-245.89
|
| Normalized EBITDA |
|
83.56
+141.48%
|
-201.44
+22.82%
|
-260.98
+2.12%
|
-266.65
|
| Reconciled Depreciation |
|
22.61
-53.76%
|
48.91
-0.18%
|
49.00
+1.55%
|
48.25
|
| EBIT |
|
-11.23
+95.15%
|
-231.87
+25.16%
|
-309.81
-5.32%
|
-294.15
|
| Total Unusual Items |
|
-72.18
-490.50%
|
18.48
+10226.26%
|
0.18
-99.14%
|
20.75
|
| Total Unusual Items Excluding Goodwill |
|
-72.18
-490.50%
|
18.48
+10226.26%
|
0.18
-99.14%
|
20.75
|
| Special Income Charges |
|
-19.89
|
0.00
+100.00%
|
-10.91
|
0.00
|
| Other Special Charges |
|
19.89
|
—
|
10.91
|
—
|
| Net Income |
|
-68.09
+75.85%
|
-281.89
+17.43%
|
-341.42
-6.42%
|
-320.83
|
| Pretax Income |
|
-68.09
+75.85%
|
-281.89
+17.43%
|
-341.42
-6.42%
|
-320.83
|
| Net Non Operating Interest Income Expense |
|
-40.36
+5.94%
|
-42.90
-110.80%
|
-20.35
+20.91%
|
-25.73
|
| Interest Expense Non Operating |
|
56.85
+13.65%
|
50.02
+58.26%
|
31.61
+18.48%
|
26.68
|
| Net Interest Income |
|
-40.36
+5.94%
|
-42.90
-110.80%
|
-20.35
+20.91%
|
-25.73
|
| Interest Expense |
|
56.85
+13.65%
|
50.02
+58.26%
|
31.61
+18.48%
|
26.68
|
| Interest Income Non Operating |
|
16.50
+131.63%
|
7.12
-36.74%
|
11.26
+1088.81%
|
0.95
|
| Interest Income |
|
16.50
+131.63%
|
7.12
-36.74%
|
11.26
+1088.81%
|
0.95
|
| Other Income Expense |
|
-72.84
-501.68%
|
18.14
+1299.40%
|
-1.51
-107.32%
|
20.66
|
| Other Non Operating Income Expenses |
|
-0.67
-90.54%
|
-0.35
+79.36%
|
-1.69
-1738.04%
|
-0.09
|
| Gain On Sale Of Security |
|
-52.28
-382.87%
|
18.48
+66.61%
|
11.09
-46.55%
|
20.75
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-68.09
+75.85%
|
-281.89
+17.43%
|
-341.42
-6.42%
|
-320.83
|
| Net Income From Continuing Operation Net Minority Interest |
|
-68.09
+75.85%
|
-281.89
+17.43%
|
-341.42
-6.42%
|
-320.83
|
| Net Income From Continuing And Discontinued Operation |
|
-68.09
+75.85%
|
-281.89
+17.43%
|
-341.42
-6.42%
|
-320.83
|
| Net Income Continuous Operations |
|
-68.09
+75.85%
|
-281.89
+17.43%
|
-341.42
-6.42%
|
-320.83
|
| Normalized Income |
|
4.09
+101.36%
|
-300.37
+12.07%
|
-341.59
0.00%
|
-341.58
|
| Net Income Common Stockholders |
|
-537.96
-42.22%
|
-378.26
+18.22%
|
-462.53
-15.68%
|
-399.83
|
| Otherunder Preferred Stock Dividend |
|
85.43
-11.35%
|
96.37
-20.43%
|
121.11
+53.30%
|
79.00
|
| Diluted EPS |
|
-3.22
-136.60%
|
-1.36
+25.03%
|
-1.82
-15.68%
|
-1.57
|
| Basic EPS |
|
-3.22
-136.60%
|
-1.36
+25.03%
|
-1.82
-15.68%
|
-1.57
|
| Basic Average Shares |
|
167.21
-39.84%
|
277.93
+9.08%
|
254.79
+0.00%
|
254.79
|
| Diluted Average Shares |
|
167.21
-39.84%
|
277.93
+9.08%
|
254.79
+0.00%
|
254.79
|
| Diluted NI Availto Com Stockholders |
|
-537.96
-42.22%
|
-378.26
+18.22%
|
-462.53
-15.68%
|
-399.83
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
0.13
-74.40%
|
0.50
|
—
|
| Depreciation And Amortization In Income Statement |
|
—
|
0.13
-74.40%
|
0.50
|
—
|
| Depreciation Income Statement |
|
—
|
0.13
-74.40%
|
0.50
|
—
|
| Preferred Stock Dividends |
|
384.44
+0.00%
|
384.44
+217.42%
|
121.11
+53.30%
|
79.00
|
| Rent And Landing Fees |
|
—
|
6.74
-16.16%
|
8.04
|
—
|
| Rent Expense Supplemental |
|
—
|
8.38
-16.02%
|
9.98
|
—
|
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Assets |
|
1,125.66
|
| Current Assets |
|
997.80
|
| Cash Cash Equivalents And Short Term Investments |
|
798.57
|
| Cash And Cash Equivalents |
|
796.27
|
| Other Short Term Investments |
|
2.29
|
| Receivables |
|
112.14
|
| Accounts Receivable |
|
112.14
|
| Other Receivables |
|
—
|
| Inventory |
|
63.62
|
| Raw Materials |
|
63.62
|
| Prepaid Assets |
|
19.59
|
| Restricted Cash |
|
1.52
|
| Other Current Assets |
|
2.35
|
| Total Non Current Assets |
|
127.86
|
| Net PPE |
|
63.17
|
| Gross PPE |
|
304.15
|
| Accumulated Depreciation |
|
-240.98
|
| Properties |
|
0.00
|
| Machinery Furniture Equipment |
|
134.11
|
| Other Properties |
|
106.23
|
| Leases |
|
63.81
|
| Goodwill And Other Intangible Assets |
|
19.34
|
| Goodwill |
|
19.34
|
| Other Non Current Assets |
|
45.35
|
| Total Liabilities Net Minority Interest |
|
548.36
|
| Current Liabilities |
|
127.14
|
| Payables And Accrued Expenses |
|
64.31
|
| Payables |
|
39.21
|
| Accounts Payable |
|
39.21
|
| Current Accrued Expenses |
|
25.11
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
31.49
|
| Current Debt And Capital Lease Obligation |
|
6.53
|
| Current Debt |
|
—
|
| Other Current Borrowings |
|
—
|
| Current Capital Lease Obligation |
|
6.53
|
| Current Deferred Liabilities |
|
24.49
|
| Current Deferred Revenue |
|
24.49
|
| Other Current Liabilities |
|
0.33
|
| Total Non Current Liabilities Net Minority Interest |
|
421.21
|
| Long Term Debt And Capital Lease Obligation |
|
421.16
|
| Long Term Debt |
|
378.45
|
| Long Term Capital Lease Obligation |
|
42.71
|
| Preferred Securities Outside Stock Equity |
|
0.00
|
| Stockholders Equity |
|
577.31
|
| Common Stock Equity |
|
577.31
|
| Capital Stock |
|
0.28
|
| Common Stock |
|
0.28
|
| Share Issued |
|
284.14
|
| Ordinary Shares Number |
|
282.53
|
| Treasury Shares Number |
|
1.61
|
| Additional Paid In Capital |
|
3,141.72
|
| Retained Earnings |
|
-2,548.74
|
| Gains Losses Not Affecting Retained Earnings |
|
0.94
|
| Treasury Stock |
|
16.90
|
| Other Equity Adjustments |
|
0.94
|
| Total Equity Gross Minority Interest |
|
577.31
|
| Total Capitalization |
|
955.76
|
| Working Capital |
|
870.65
|
| Invested Capital |
|
955.76
|
| Total Debt |
|
427.69
|
| Net Debt |
|
—
|
| Capital Lease Obligations |
|
49.24
|
| Net Tangible Assets |
|
557.96
|
| Tangible Book Value |
|
557.96
|
| Derivative Product Liabilities |
|
0.05
|
| Interest Payable |
|
—
|
| Other Equity Interest |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
83.16
+133.91%
|
-245.20
+11.19%
|
-276.10
+3.36%
|
-285.71
|
| Cash Flow From Continuing Operating Activities |
|
83.16
+133.91%
|
-245.20
+11.19%
|
-276.10
+3.36%
|
-285.71
|
| Net Income From Continuing Operations |
|
-68.09
+75.85%
|
-281.89
+17.43%
|
-341.42
-6.42%
|
-320.83
|
| Depreciation Amortization Depletion |
|
22.61
-53.76%
|
48.91
-0.18%
|
49.00
+1.55%
|
48.25
|
| Depreciation And Amortization |
|
22.61
-53.76%
|
48.91
-0.18%
|
49.00
+1.55%
|
48.25
|
| Other Non Cash Items |
|
19.57
+17.28%
|
16.69
+99.09%
|
8.38
+20.12%
|
6.98
|
| Stock Based Compensation |
|
70.01
+275.51%
|
18.64
+22.32%
|
15.24
-33.45%
|
22.90
|
| Operating Gains Losses |
|
19.89
|
—
|
10.91
|
—
|
| Unrealized Gain Loss On Investment Securities |
|
52.28
+382.87%
|
-18.48
-66.61%
|
-11.09
+46.55%
|
-20.75
|
| Change In Working Capital |
|
-33.13
-13.97%
|
-29.07
-307.73%
|
-7.13
+67.97%
|
-22.26
|
| Change In Receivables |
|
-29.79
+11.91%
|
-33.82
-124.23%
|
-15.08
-26.68%
|
-11.90
|
| Changes In Account Receivables |
|
-29.79
+11.91%
|
-33.82
-124.23%
|
-15.08
-26.68%
|
-11.90
|
| Change In Inventory |
|
-20.75
-480.11%
|
5.46
+223.09%
|
-4.43
+60.06%
|
-11.10
|
| Change In Prepaid Assets |
|
-5.15
-265.77%
|
-1.41
-130.99%
|
4.54
+228.22%
|
-3.54
|
| Change In Payables And Accrued Expense |
|
22.51
+3801.91%
|
0.58
-93.16%
|
8.43
+264.66%
|
2.31
|
| Change In Accrued Expense |
|
11.48
+1329.51%
|
0.80
-36.27%
|
1.26
+119.10%
|
-6.60
|
| Change In Payable |
|
11.04
+4982.74%
|
-0.23
-103.15%
|
7.17
-19.52%
|
8.91
|
| Change In Account Payable |
|
11.04
+4982.74%
|
-0.23
-103.15%
|
7.17
-19.52%
|
8.91
|
| Change In Other Current Assets |
|
0.05
-60.33%
|
0.12
+120.58%
|
-0.59
-129.64%
|
1.98
|
| Investing Cash Flow |
|
-16.26
-130.72%
|
52.93
-75.35%
|
214.77
+175.90%
|
-282.99
|
| Cash Flow From Continuing Investing Activities |
|
-16.26
-130.72%
|
52.93
-75.35%
|
214.77
+175.90%
|
-282.99
|
| Net PPE Purchase And Sale |
|
-16.26
-92.56%
|
-8.44
+62.17%
|
-22.32
+47.18%
|
-42.26
|
| Purchase Of PPE |
|
-16.26
-92.56%
|
-8.44
+62.17%
|
-22.32
+47.18%
|
-42.26
|
| Capital Expenditure |
|
-16.26
-92.56%
|
-8.44
+62.17%
|
-22.32
+47.18%
|
-42.26
|
| Net Investment Purchase And Sale |
|
0.00
-100.00%
|
61.38
-74.11%
|
237.09
+198.49%
|
-240.73
|
| Purchase Of Investment |
|
0.00
|
0.00
+100.00%
|
-63.40
+83.25%
|
-378.38
|
| Sale Of Investment |
|
0.00
-100.00%
|
61.38
-79.57%
|
300.49
+118.31%
|
137.65
|
| Financing Cash Flow |
|
664.99
+232.01%
|
200.29
+1876.83%
|
10.13
-3.00%
|
10.45
|
| Cash Flow From Continuing Financing Activities |
|
664.99
+232.01%
|
200.29
+1876.83%
|
10.13
-3.00%
|
10.45
|
| Net Issuance Payments Of Debt |
|
27.76
-86.11%
|
199.82
+1790.99%
|
10.57
+1198.44%
|
-0.96
|
| Issuance Of Debt |
|
27.86
-86.07%
|
199.98
+4.53%
|
191.31
|
0.00
|
| Repayment Of Debt |
|
-0.11
+32.48%
|
-0.16
+99.91%
|
-180.74
-18688.25%
|
-0.96
|
| Long Term Debt Issuance |
|
27.86
-86.07%
|
199.98
+4.53%
|
191.31
|
0.00
|
| Long Term Debt Payments |
|
-0.11
+32.48%
|
-0.16
+99.91%
|
-180.74
-18688.25%
|
-0.96
|
| Net Long Term Debt Issuance |
|
27.76
-86.11%
|
199.82
+1790.99%
|
10.57
+1198.44%
|
-0.96
|
| Net Common Stock Issuance |
|
528.35
|
0.00
|
0.00
|
—
|
| Common Stock Payments |
|
-0.11
|
0.00
|
0.00
|
—
|
| Repurchase Of Capital Stock |
|
-0.11
|
0.00
|
0.00
|
—
|
| Proceeds From Stock Option Exercised |
|
17.91
+1070.39%
|
1.53
-17.96%
|
1.86
-83.65%
|
11.41
|
| Net Other Financing Charges |
|
-30.26
-2757.51%
|
-1.06
+53.96%
|
-2.30
|
—
|
| Changes In Cash |
|
731.88
+9020.05%
|
8.03
+115.68%
|
-51.19
+90.83%
|
-558.25
|
| Effect Of Exchange Rate Changes |
|
0.13
+3350.00%
|
-0.00
-106.45%
|
0.06
+3000.00%
|
0.00
|
| Beginning Cash Position |
|
68.03
+13.37%
|
60.01
-46.01%
|
111.14
-83.40%
|
669.38
|
| End Cash Position |
|
800.04
+1076.05%
|
68.03
+13.37%
|
60.01
-46.01%
|
111.14
|
| Free Cash Flow |
|
66.89
+126.37%
|
-253.64
+15.00%
|
-298.42
+9.01%
|
-327.96
|
| Interest Paid Supplemental Data |
|
43.52
-11.21%
|
49.02
+210.71%
|
15.78
-34.92%
|
24.24
|
| Common Stock Issuance |
|
528.46
|
0.00
|
0.00
|
—
|
| Issuance Of Capital Stock |
|
649.70
|
0.00
|
0.00
|
—
|
| Net Preferred Stock Issuance |
|
121.24
|
0.00
|
0.00
|
—
|
| Preferred Stock Issuance |
|
121.24
|
0.00
|
0.00
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 42026-06-02 View
- 42026-06-02 View
- 42026-05-18 View
- 42026-05-18 View
- 42026-05-18 View
- 42026-05-18 View
- 42026-05-18 View
- 42026-05-12 View
- 10-Q2026-05-08 View
- 8-K2026-05-07 View
- 8-K2026-04-02 View
- 42026-03-10 View
- 42026-03-10 View
- 42026-03-10 View
- 42026-03-10 View
- 42026-03-10 View
- 10-K2026-03-03 View
- 42026-03-02 View
- 42026-02-27 View
- 42026-02-27 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|